Abstract 1863
Background
The waiting time for cancer diagnosis and treatment could influence patients’ survival. However, in Poland the waiting time is still long. In Poland, medical care is financed by the government and free for patients, but in a situation of long waiting times for diagnostic tests or in cases where it is impossible to obtain some other health services, patients use the private sector. The rationale for this study was to figure out if there are any difficulties in the oncological system and assessment of whether patients have to use the private sector.
Methods
The study was carried out on a group of 384 patients who were being treated for malignant neoplasm in five oncological centers in Poland. A questionnaire was prepared specifically for this study and each patient was interviewed individually. The questionnaire was validated on a group of 20 patients. The measure of compliance was calculated using Cohen’s Kappa coefficient. The study protocol was approved by the Local Ethics Committee. All of the participants had submitted a signed consent form.
Results
202 women and 180 men (2 no data) were analyzed, median age 65 years. 67% of patients declared problems with getting social service and significant differences in getting social service were observed between various regions of Poland (p < 0.001). One third of patients (32%) used private services during the diagnostic process. Patients with higher education showed significantly more frequent problems (p = 0.03). 91% of patients declared difficulties during treatment. Those who showed significantly more frequent problems were: women (p = 0.04), younger patients (p = 0.0015), professionally active (p = 0.025) with higher education (p < 0.001), living in cities (p = 0.016). More than half of patients with higher education (54%) paid for healthcare services in comparison with patients with lower education levels (average 25%) (p < 0.001).
Conclusions
Cancer patients have some difficulties in the oncological system in Poland. The younger people, those with higher education, the professionally active, and those living in cities seem to be more aware of their rights. The proper solution could be to introduce corrections in oncological organization to avoid the need of using private services.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1984 - Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC)
Presenter: Gizem Kaval
Session: Poster Display session 3
Resources:
Abstract
4822 - Efficiacy of different nutritional intervention on nutritional status and quality of life for local advanced nasopharyngeal carcinoma patients: a prospective clinical trial
Presenter: Yuan-yuan Chen
Session: Poster Display session 3
Resources:
Abstract
2628 - Apatinib in treating patients with platinum-resistant or platinum-refractory recurrent or metastatic nasopharyngeal carcinoma
Presenter: Changjuan Tao
Session: Poster Display session 3
Resources:
Abstract
4887 - Impact of tumor site and adjuvant radiotherapy on survival of adenoid cystic carcinoma: a SEER database analysis
Presenter: Jason Tasoulas
Session: Poster Display session 3
Resources:
Abstract
2634 - Efficacy and safety of anlotinib for patients with recurrent and/or metastatic salivary gland carcinomas
Presenter: Wen Jiang
Session: Poster Display session 3
Resources:
Abstract
3568 - ACCURACY a phase (P) 2 trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notch act mut): preliminary safety and efficacy data.
Presenter: Renata Ferrarotto
Session: Poster Display session 3
Resources:
Abstract
683 - Pathologic Staging Changes in Oral Cavity Squamous Cell Carcinoma—Stage Migration and Implications for Adjuvant Treatment
Presenter: Zain Husain
Session: Poster Display session 3
Resources:
Abstract
563 - Expression of immune response biomarkers in head and neck squamous cell carcinoma (HNSCC) in irradiated area
Presenter: Carole Pflumio
Session: Poster Display session 3
Resources:
Abstract
4030 - HLA-Ligandome analysis reveals target antigens of oropharyngeal squamous cell carcinoma
Presenter: Simon Laban
Session: Poster Display session 3
Resources:
Abstract
2979 - Topographical distribution of sentinel lymph nodes in early tongue squamous cell carcinomas
Presenter: Hiroyuki Goda
Session: Poster Display session 3
Resources:
Abstract